Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline.

Saccharomyces boulardii, a probiotic yeast is well prescribed for various gastrointestinal disorders accompanied by gut dysbiosis such as inflammatory bowel disease, bacterial diarrhea and antibiotic associated diarrhea. Gut dysbiosis has been associated with central nervous system via gut brain axis primarily implied in the modulation of psychiatric conditions. In the current study we use Saccharomyces boulardii as a therapeutic agent against gut dysbiosis associated cognitive decline. In mice, gut dysbiosis was induced by oral Ampicillin Na (250 mg/kg twice-daily) for 14 days. While in the treatment group S. boulardii (90 mg/kg once a day) was administered orally for 21 days along with 14 days of antibiotic treatment. Gene expression studies revealed antibiotic mediated decrease in the Lactobacillus, Bifidobacterium, Firmicutes and Clostridium which were restored by S. boulardii treatment. Cognitive behavioral studies showed a parallel reduction in fear conditioning, spatial as well as recognition memory which were reversed upon S. boulardii treatment in these animals. S. boulardii treatment reduced myeloperoxidase enzyme, an inflammatory marker, in colon as well as brain which was increased after antibiotic administration. Similarly, S. boulardii reduced the brain acetylcholine esterase, oxidative stress and inflammatory cytokines and chemokines which were altered due to antibiotic treatment. S. boulardii treatment also protected hippocampal neuronal damage and restored villus length and crypt depth thus normalizing gut permeability in antibiotic treated animals. Hence, we conclude that S. boulardii prevented antibiotic associated gut dysbiosis leading to reduced intestinal and brain inflammation and oxidative stress thus preventing hippocampal neuronal damage and eventually reversing gut dysbiosis associate cognitive decline in mice.

Flavonoid-rich wheatgrass (Triticum aestivum L.) diet attenuates diabetes by modulating antioxidant genes in streptozotocin-induced diabetic rats.

Wheatgrass, young germinated shoots of Triticum aestivum L., is proclaimed as antidiabetic nutraceutical by traditional medicines across the world. In this study, the effects of the wheatgrass diet in ameliorating oxidative stress (OS) induced during diabetes were investigated. Total phenolic and flavonoid contents (TPC and TFC) and in vitro antioxidant activity of wheatgrass extract were estimated at different days (5, 7, 9, 11, 13, and 15) after germination. Correlating the TPC and TFC with in vitro antioxidant activity, 9th DAG wheatgrass was found to possess maximum antioxidant potential. UHPLC-MS/MS analysis also revealed the presence of nine flavonoids. For in vivo studies, diabetes was induced by streptozotocin in Wistar rats fed with a high-fat diet. Concomitant administration of 9th-day wheatgrass diet (200 and 400 mg/kg) for 60 days exhibited significant improvements in hyperglycemia, body weight, lipid profile, biochemical indices (AST, ALT, GSH, GPx), and restoration of tissue architectures equivalent to normal rats. Further, qRT-PCR-based expression profiling revealed a significant modulation of major antioxidant marker genes and insulin gene which substantiated that the wheatgrass diet is effective in reducing OS during diabetes. Therefore, flavonoid-rich 9th-day wheatgrass could be used as a functional food to control diabetes. PRACTICAL APPLICATIONS: The present research supported that wheatgrass protects against oxidative stress and therefore could be utilized to ameliorate diabetes. The findings may contribute to the development and formulation of wheatgrass-based functional food or dietary supplement for diabetes by nutraceutical industries.